As expected, the European Commission approves Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide), a once-weekly human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of adults with type 2 diabetes when metformin is contraindicated or not tolerated.
The advisory group CHMP adopted a positive opinion backing approval in December.
Ozempic was approved in the U.S. in December and in Canada last month.
Previously: European advisory group backs Novo's Ozempic for T2D (Dec. 15, 2017)
Subscribe for full text news in your inbox